BeiGene | A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Beigene Study ID

BGB-3111-106

ClinicalTrials.gov ID

NCT03432884

Study Overview

Sex: All

Age: 18 Years / 55 Years

No Study Documents

Study Overview

Sex: All

Age: 18 Years / 55 Years

No Study Documents